Advertisement

Acta Diabetologica

, Volume 51, Issue 3, pp 505–508 | Cite as

Regression of diabetic macular edema after subcutaneous exenatide

  • Valentina Sarao
  • Daniele Veritti
  • Paolo Lanzetta
Case Report

Abstract

The aim of this study is to report a case of complete regression of diabetic macular edema after subcutaneous injection of exenatide in a patient with type 2 diabetes mellitus. This study is an interventional case report. Blood investigations, complete ophthalmic examinations and optical coherence tomography were performed. A 55-year-old female affected by poorly controlled type 2 diabetes mellitus presented with visual impairment due to macular edema in the right eye. The left eye showed mild edema without visual loss. Best-corrected visual acuity (BCVA) was 20/80 and 20/20, respectively. The patient was encouraged to improve metabolic control, and the antidiabetic therapy was modified combining exenatide 10 μg subcutaneously twice daily to her regimen of oral metformin. The patient did not receive any ocular treatment. A complete tomographic resolution of macular edema was observed after 1 month and BCVA improved to 20/63. These findings were confirmed for the entire 6-month follow-up duration. No ocular or non-ocular adverse events were recorded. This is the first reported case of complete regression of macular edema in a diabetic patient after subcutaneous injection of exenatide.

Keywords

Diabetic macular edema Exenatide Vascular endothelial growth factor 

Notes

Acknowledgments

No potential conflicts of interest relevant to this article were reported. This research did not receive any specific grant from any funding agency in the public, commercial or not-for-profit sector.

Conflict of interest

None.

References

  1. 1.
    Bandello F, Battaglia Parodi M, Lanzetta P et al (2010) Diabetic macular edema. Dev Ophthalmol 47:73–110PubMedCrossRefGoogle Scholar
  2. 2.
    MacDonald PE, El-Kholy W, Riedel MJ, Salapatek AM, Light PE, Wheeler MB (2002) The multiple actions of GLP-1 on the process of glucose-stimulated insulin secretion. Diabetes 51:S434–S442PubMedCrossRefGoogle Scholar
  3. 3.
    The Diabetes Control and Complications Trial Research Group (1995) The relationship of glycemic exposure (HbA1c) to the risk of development and progression of retinopathy in the diabetes control and complications trial. Diabetes 44:968–983CrossRefGoogle Scholar
  4. 4.
    Wu JD, Xu XH, Zhu J et al (2011) Effect of exenatide on inflammatory and oxidative stress markers in patients with type 2 diabetes mellitus. Diabetes Technol Ther 13:143–148PubMedCrossRefGoogle Scholar
  5. 5.
    Xie XY, Mo ZH, Chen K et al (2011) Glucagon-like peptide-1 improves proliferation and differentiation of endothelial progenitor cells via upregulating VEGF generation. Med Sci Monit 17:35–41CrossRefGoogle Scholar
  6. 6.
    Zhang Y, Zhang J, Wang Q et al (2011) Intravitreal injection of exendin-4 analogue protects retinal cells in early diabetic rats. Invest Ophthalmol Vis Sci 52:278–285PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Italia 2013

Authors and Affiliations

  • Valentina Sarao
    • 1
  • Daniele Veritti
    • 1
    • 2
  • Paolo Lanzetta
    • 1
    • 2
  1. 1.Department of OphthalmologyUniversity of UdineUdineItaly
  2. 2.Istituto Europeo di Microchirurgia Oculare (IEMO)UdineItaly

Personalised recommendations